Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's Lymphoma

NCT05771883 is registered in ClinicalTrials.gov with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. as lead sponsor.

NCT NCT05771883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05771883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/IIa Clinical Study of IMM0306 fo r Injection in Combination With Lenalidomide for the Treatment of Relapsed/Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Cell Non-Hodgkin's Lymphoma
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2023
Completion date
November 30, 2025
Enrollment
102 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin's lymphoma